Expertos Invitados




Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
RESULTADOS DE LA RADIOTERAPIA ADYUVANTE EN PACIENTES CON CÁNCER DE ESÓFAGO SOMETIDOS A ESOFAGECTOMÍA
Saudi Medical Journal 45(9):900-910
Difundido en siicsalud: 11 dic 2024
DOLOR POSOPERATORIO EN EL SÍNDROME DEL TÚNEL CARPIANO
Acta Ortopédica Brasileira 32(4):1-5
Difundido en siicsalud: 3 dic 2024

AVANCES EN LA UTILIZACION DE TAXANOS EN LA TERAPIA ADYUVANTE DEL CANCER DE MAMA

(especial para SIIC © Derechos reservados)
Esta revisión analiza la información disponible acerca del papel de los taxanos en el tratamiento adyuvante del cáncer de mama.
nabholtz9.jpg Autor:
Jean-marc Nabholtz
Columnista Experto de SIIC

Institución:
Breast Cancer Research Institute

Artículos publicados por Jean-marc Nabholtz
Coautor
Joseph Gligorov* 
Medical Oncology Department, CancerEst APHP Tenon 4, Francia*
Recepción del artículo
29 de Septiembre, 2005 		Aprobación
6 de Octubre, 2005
Primera edición
21 de Marzo, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

AVANCES EN LA UTILIZACION DE TAXANOS EN LA TERAPIA ADYUVANTE DEL CANCER DE MAMA

Resumen
El cáncer de mama es el tipo de cáncer más frecuente en las mujeres de los países desarrollados. La quimioterapia sistémica contribuyó a mejorar en forma sorprendente la supervivencia global de las pacientes tratadas por cáncer de mama invasor, en estadio temprano. Entre los nuevos agentes quimioterapéuticos recientemente introducidos, los taxanos han surgido como los compuestos más potentes desde los regímenes con antraciclinas. Ambos taxanos disponibles (paclitaxel y docetaxel) demostraron una actividad importante y un impacto en la supervivencia de esta población, pero presentan algunas diferencias significativas en términos del perfil preclínico y principalmente en las características clínicas. En la práctica clínica, los taxanos constituyen uno de los tratamientos adyuvantes convencionales para las pacientes con cáncer de mama y compromiso ganglionar, utilizados como quimioterapia secuencial o en combinación con antraciclinas. Esta revisión se concentra en los datos disponibles acerca del papel de los taxanos en el tratamiento adyuvante del cáncer de mama.

Palabras clave
Cáncer de mama, adyuvante, taxanos, paclitaxel, docetaxel, antraciclinas


Artículo completo
(castellano)
Extensión:  +/-16.52 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

ADVANCES IN THE USE OF TAXANES IN THE ADJUVANT THERAPY OF BREAST CANCER

Abstract
Breast cancer is the most frequent cancer for women in developed countries. Systemic chemotherapies have contributed to dramatically improve overall survival of patient treated for early stage invasive breast cancer. Among the novel chemotherapeutic agents recently introduced, the taxanes have emerged as the most powerful compounds since anthracycline regimens. Both of available taxanes (paclitaxel and docetaxel) have demonstrate important activity and impact on the survival of these population but they have some significant differences in terms of preclinical profile and, most importantly, clinical characteristics. In clinical practice, the taxanes are now one of the standard adjuvant therapies for patient with node positive breast cancer, used either as sequential chemotherapy or in combination with anthracyclines. This review will focus on available data on the role of taxanes in the adjuvant treatment of breast cancer.

Key words
 Breast cancer, adjuvant, taxanes, paclitaxel, docetaxel, anthracyclines


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Farmacología, Oncología
Relacionadas: Medicina Farmacéutica, Obstetricia y Ginecología



Comprar este artículo
Extensión: 16.52 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Greenlee RT, Hill-Harmon MB, Murray Y, t al. Cancer statistics, 2001. CA Cancer J Clin (2001); 51:15-36.
  2. Early Breast Cancer Trialists’ Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-717.
  3. Wani MC, Taylor HL, Wall ME, Coggon P, Mcphail AT. lant antitumour agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevifolia. J Am Chem Soc (1971); 93:2325-2327.
  4. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (Taxol). N Engl J Med (1995); 332:1004-1014.
  5. Lavelle F, Gueritte-Voegelein F, Guenard D. Le taxotere: des aiguilles d'if a la clinique. Bull Cancer (1993); 80:326-338.
  6. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004; 9 (Suppl 2):3-8.
  7. Nabholtz JM, Tonkin K, Smylie M, et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer Expert Opin Pharmacother. 2000; 1:187-206.
  8. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996); 14:1858-1867.
  9. Peretz T, Sulkes A, Chollet P, et al. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer (1995); 31 (Suppl 5):S75a.
  10. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. (2004); 22: 2061-8.
  11. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. (1999); 17: 3403-11.
  12. Holmes FA, Valero V, Buzdar AU, et al. Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patient (pt) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol (1998); 17: 110a.
  13. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. (2000); 18: 724-33.
  14. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. (2003); 21: 588-92.
  15. Bishop J, Dewar J, Toner G, et al. Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer. J Clin Oncol (1999); 17: 2355-2364
  16. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. (2001); 19: 4216-23.
  17. Green MC, Buzdar AU, Smith T, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC—final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol (2002); 21: 35a.
  18. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Pros Am Soc Clin Oncol (2004); 22: 512a.
  19. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol (1997); 15: 1906-15.
  20. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicine in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-sequence-finding study. J. Clin. Oncol. (1995); 13: 2688-2699.
  21. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphomide as first-line therapy for women with metastatic breast cancer: results of a randomized phase III multicenter trial. J Clin Oncol (2001); 19:1707-1715.
  22. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol (2002); 20: 3114-3121.
  23. Luck HJ, Thomssen C, Untch M, et al. Multicentric Phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol (2000);19: 280a.
  24. Carmichael J. UKCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol (2001); 20: 22a (abstract 84).
  25. Gianni L, Baselga J, Eiermann W et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). Proc Am Soc Clin Oncol (2005), 24: 513a.
  26. Dieras V, Fumoleau P, Romieu G ET AL. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004; 22: 4958-65.
  27. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. (1999) 17(8): 2341-2354.
  28. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. (1999) 17(5): 1413-1424.
  29. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999; 35(8):1194-201.
  30. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer. (2002); 87(11):1210-5.
  31. Loffler TM. Is there a place for “dose-dense” weekly schedules of the taxoids Semin Oncol (1998); 25 (Suppl 12): 32-34.
  32. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 1997;11 Suppl 8:5–18.
  33. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003;88:1339–45.
  34. Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel is effective as neoadjuvant chemotherapy for stage II and III breast cancer. Efficacy and correlation with biological markers in a Phase II, multicenter study. Clin Cancer Res 2003; 9: 686–92.
  35. Nabholtz JM. Docetaxel (taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin. Oncol. 1999; 26 (Suppl 9): 7-13.
  36. Rudek MA, Sparreboom A, Garrett-Mayer ES et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. (2004); 40: 1170-8.
  37. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol (2003); 21: 968-975.
  38. Nabholtz J, Paterson A, Dirix L, et al. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol (2001); 20:22a.
  39. Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol (2002), 21: 35a.
  40. Bontenbal M, Braun JJ, Creemers GJ, et al. Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer (2003); 1: S201 (abstr 671).
  41. Bonneterre J, Dieras V, Tubiana-Hulin M, Et AL. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. (2004); 91: 1466-71.
  42. Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005; 23:2988-95.
  43. Luporsi L, Vanlemmens L, Coudert B et al. Six cycles of FEC 100 vs 6 cycles of epirubicin–docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomized phase II trial of Girec S01. Proc Am Soc Clin Oncol 2000;19: 92a.
  44. Bear HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat (2004); 88 (suppl 1): 26a.
  45. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 1456-66.
  46. Von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005; 23: 2676-85.
  47. Nabholtz JM, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother. (2005); 6: 1073-94.
  48. Ravdin P, Erban J, Overmoyer B, et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl. (2003); 1: S201. 670a.
  49. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. (2003); 21: 976-83.
  50. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. (2005); 23: 3686-96.
  51. Buzdar AU, Singletary SE, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. (2002); 8: 1073-9.
  52. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol (2002); 21: 143A.
  53. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. (2003); 21: 1431-9. Erratum in: J Clin Oncol. (2003); 21: 2226.
  54. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol (1997); 15: 1858-1869.
  55. Fisher B, Anderson S, Decillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from the national surgical adjuvant breast and bowel project B-25. J Clin Oncol (1999); 17: 3374-3388.
  56. Gasparini G. Metronomic scheduling: the future of chemotherapy Lancet Oncol (2001); 2: 733-740.
  57. Loesch D, Greco FA, O’Shaugnessy J, et al. A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res Treat (2004); 88 (suppl 1): 28a.
  58. Nabholtz JM, Pienkowsi T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol (2002); 21:141a.
  59. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. (2005); 352: 2302-13.
  60. Nabholtz JM, Cantin J, Chang J, et al. Phase III trial comparing granulocyte colony-stimulating factor (G-CSF) to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophospamide (TAC): results of the BCIRG 004 trial. Clin Breast Cancer (2002); 3(4): 268-75.
  61. Goldstein L, O’Neill A, Sparano J et al. E2197: Phase III AT (doxorubucin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc Am Soc Clin Oncol 2005; abs 512.
  62. Roche H, Fumoleau P, Spielmann M, et al. Five Years Analysis of the PACS 01 trial: 6 Cycles of FEC100 Vs. 3 Cycles of FEC100 Followed by 3 Cycles of Docetaxel (D) for the Adjuvant Treatment of Node Positive Breast Cancer. Br Cancer Res Treat (2004); 83: 27a.
  63. Nabholtz JM, Riva A. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies. Clin Breast Cancer. (2001); 2 Suppl 1:S7-14.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
Artículos relacionadosMás relacionadosAtículos relacionados
ALGORITMOS DE APRENDIZAJE PROFUNDO PARA LA DETECCIÓN DEL CÁNCER DE MAMA
Radiology 313(2):1-10
Difundido en siicsalud: 26 nov 2024
ABORDAJE DEL CÁNCER DE MAMA LOCALMENTE AVANZADO EN AMÉRICA LATINA
JCO Global Oncology 10:1-15
Difundido en siicsalud: 29 nov 2024
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008